Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Jessicaemerrill
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Jessicaemerrill
-
$MRK's effort to get smaller follows a growing industry trend among big pharmas to focus on select therapeutic areas and high-growth innovative brands. But Merck's decision came as a bit of a surprise; CEO Frazier said it was considered for some time.https://scrip.pharmaintelligence.informa.com/articles/2020/02/05/merck-to-spin-out-a-new-company-following-industrys-downsizing-trend …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Jessica Merrill proslijedio/la je Tweet
$GSK splitting into two: 1. biopharma company focused on 'science related to the immune system, use of genetics and new technologies'. 2. leader in consumer healthcare.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jessica Merrill proslijedio/la je Tweet
Merck will spin off about 90 products forecast sell $6.5 billion this year, including cholesterol drug Zetia, into a new, publicly-traded company next year.https://www.wsj.com/articles/merck-to-spin-off-slow-growth-products-into-new-company-11580903102 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
They finally got me on a podcasthttps://twitter.com/Datamonitor_MR/status/1223002407858081792 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Breakfast for dinner is when you are failing as a parent...or winning?
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$BIIB will increase spending in 2020 to build out a commercial infrastructure to support the launch of#aducanuamb and its already startinghttps://scrip.pharmaintelligence.informa.com/articles/2020/01/30/biogen-is-putting-its-money-where-its-mouth-is--behind-the-launch-of-aducanumab …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
$AMGN#biosimilar revenues of $568m,$BIIB of $738m and$PFE of $911m in 2019; looks like biosimilars are becoming material to the top line. But for each company it is a portfolio of products and US and Europe.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$NVS#Zolgensma made $390m in 2019, approved midyear in children under 2. It's on a partial trial hold in older patients. I talked to#AveXis President Lennon on the relationship with FDA, the clinical hold and expansion in gene therapyhttps://pink.pharmaintelligence.informa.com/articles/2020/01/28/novartis-avexis-president-lennon-on-rebuilding-trust-with-fda-zolgensma-trial-hold-and-more …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Pretty interesting that after such a slow start
$PFE's#biosimilar business has grown into a nearly billion dollar business, up 22% to $911m in 2019.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Jessica Merrill proslijedio/la je Tweet
In
@PharmaPinkSheet's latest Drug Review Profile, we take a deep dive into@US_FDA review documents for$SRPT's Vyondyshttps://pink.pharmaintelligence.informa.com/articles/2020/01/27/with-sareptas-vyondys-us-fda-staff-saw-opportunity-to-right-perceived-wrongs-with-exondys …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I talked to
$NVS new pharma president about several launches and how the company is viewing#inclisiran as a "vaccines-like" approach to cholesterol.https://twitter.com/PharmaScrip/status/1221901807636701184 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Payers are easing restrictions, like step edits, among branded I&I drugs, according to a Bernstein analysis.
#Humira is not a required step edit in dermatology or RA anymore, and that could have implications for biosimilars eventually.https://scrip.pharmaintelligence.informa.com/articles/2020/01/22/fewer-us-market-access-restrictions-for-branded-ii-drugs-will-drive-growth …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
FDA believes this is the first study to investigate a variety of proprietary prescription drug names. story by
@brendasandburghttps://pink.pharmaintelligence.informa.com/articles/2020/01/20/power-of-proprietary-drug-names-to-be-studied-by-us-fda …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jessica Merrill proslijedio/la je Tweet
What a week it’s been - and it’s only Thursday! Here’s our (free)
#JPM20 Day 3 roundup. One more Notebook to come & many stories to follow over the coming weeks from insightful interviews@PharmaScrip &@PharmaPinkSheet did on the ground in San Francisco.https://scrip.pharmaintelligence.informa.com/SC141479/JP-Morgan-Notebook-Day-3-Skyrizi-Momentum-Builds-Whats-Next-For-Amarin-Viatris-Debuts-And-More …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.